These effects are typically mild to moderate and decrease as treatment continues
What you need to know, Harvard Health Publishing (2024) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, Food and Drug Administration (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
However, seek urgent medical advice if you experience severe persistent abdominal pain, continuous vomiting, or signs of dehydration
Although early trial results are encouraging, retatrutide is not yet approved for use in the UK or elsewhere
Women showed a 31% nausea rate versus 24% for men
MOTS-C improves it through AMPK activation in skeletal muscle, which is the largest insulin-responsive tissue in your body